MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has successfully migrated to a DEA-approved telemedicine platform, marking a significant advancement in its capabilities. This new system allows MangoRx's third-party doctor network to prescribe controlled substances, including Prime by MangoRx, an Oral Testosterone Replacement Therapy. The platform has accelerated the company's timeline for introducing new product lines, particularly the Slim and Trim weight loss products featuring Semaglutide and Tirzepatide in oral dissolvable tablets.

The company expects to launch these products before the end of Q3, capitalizing on the high demand for GLP-1 weight loss treatments. MangoRx has also unveiled a redesigned website with improved UI/UX, optimized for enhanced customer workflows. The HIPAA-compliant system ensures regulatory compliance and data security, setting a new benchmark for excellence in telemedicine.

Positive

• Successful migration to a DEA-approved telemedicine platform, enhancing capabilities and regulatory compliance
• Ability to prescribe controlled substances, expanding product offerings
• Accelerated timeline for introducing new product lines, particularly weight loss treatments
• Anticipated launch of Slim and Trim products featuring Semaglutide and Tirzepatide before end of Q3
• Improved website with enhanced UI/UX, potentially increasing customer engagement and satisfaction
• HIPAA-compliant system ensuring data security and patient confidentiality

Negative

• None.

Insights

Medical Technology Analyst

MangoRx's migration to a DEA-approved telemedicine platform is a significant leap forward in the DTC telemedicine space. This upgrade enables the company to prescribe controlled substances, including their Prime TRT product and upcoming weight loss treatments. The integration with Surescripts enhances prescription management, potentially improving patient adherence and satisfaction.

The accelerated timeline for launching Slim and Trim, featuring Semaglutide and Tirzepatide, could be a game-changer. These GLP-1 agonists have shown remarkable efficacy in weight loss and offering them in an oral dissolvable format may provide a competitive edge over injectable alternatives. However, it's important to monitor how this formulation compares in bioavailability and efficacy to traditional delivery methods.

The enhanced HIPAA-compliant system with improved UI/UX should streamline operations and boost patient engagement. This could lead to better retention rates and increased recurring revenue. The real-time data tracking capabilities also open doors for personalized treatment plans and data-driven decision-making in patient care.

Financial Analyst

MangoRx's strategic move positions them favorably in the rapidly growing telemedicine and weight loss markets. The accelerated launch of GLP-1 weight loss treatments before Q3 end could significantly impact revenue. With the global weight loss drugs market projected to reach $50 billion by 2030, even a small market share could translate to substantial growth.

The expanded product portfolio, including controlled substances, diversifies revenue streams and may improve customer lifetime value. The ability to offer auto-refills could lead to more predictable, recurring revenue. However, investors should watch for increased operating costs associated with the new system and potential regulatory challenges in the controlled substances space.

While the news is promising, MangoRx's ability to execute effectively and capture market share in the competitive weight loss sector will be crucial. The company's NASDAQ listing (MGRX) provides liquidity, but as a smaller player, it may face challenges competing with established pharmaceutical giants. Investors should monitor customer acquisition costs, retention rates and margins in the coming quarters to gauge the financial impact of these developments.

Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx’s capabilities, reinforcing its commitment to innovation and superior patient care.

The new operating system, authorized by the DEA and integrated with Surescripts, allows MangoRx’s third-party doctor network to prescribe and offer controlled substances, including Prime by MangoRx, powered by Kyzatrex, an Oral Testosterone Replacement Therapy (TRT), as well as other hormone replacement therapies. This approval not only distinguishes MangoRx in the Direct-to-Consumer (DTC) telemedicine space but also validates the Company’s cutting-edge technology and regulatory compliance.

Crucially, this advanced system has accelerated the Company’s ability to introduce new product lines, including the highly anticipated compounded weight loss products, Slim and Trim, featuring Semaglutide and Tirzepatide in an oral dissolvable tablet. The Company anticipates making these products available to patients before the end of the third quarter, capitalizing on the significant demand for GLP-1 weight loss treatments and promising substantial revenue growth for MangoRx. The enhanced capabilities of the new operating system will enable a swift response to market needs, allowing MangoRx to launch new products and treatments much faster than previously anticipated, solidifying the Company’s competitive edge.

Amanda Hammer, COO of MangoRx, underscores the system’s transformative impact: “The migration to our DEA-approved operating system marks a pivotal achievement for MangoRx. This advanced system empowers us to offer a broader range of products and respond swiftly to market demands. Our commitment to regulatory compliance and innovation ensures that we deliver exceptional value to our patients and stakeholders. We’re excited about the growth opportunities this system brings and look forward to revolutionizing patient care in the telemedicine industry.”

In conjunction with the system upgrade, MangoRx has unveiled a redesigned consumer-facing website featuring an improved user interface and user experience (UI/UX), optimized for enhanced customer workflows. The new site, coupled with the system’s real-time data tracking and seamless integration, significantly enhances operational efficiency, patient engagement, and overall satisfaction, further reinforcing MangoRx’s dedication to providing superior patient care.

Jacob Cohen, CEO and Co-Founder of MangoRx, states: “This milestone represents our dedication to revolutionizing patient care. Our new system enhances patient management, offering seamless doctor visits, prescription auto-refills, and overall health management. The accelerated launch of our GLP-1 weight loss treatments underscores our mission to leverage technology for superior patient care. The successful migration to the DEA-approved system signals a transformative phase for MangoRx, setting a new benchmark for excellence in telemedicine.”

The HIPAA-compliant system ensures all operations adhere to stringent regulatory standards, providing patients with secure and reliable healthcare solutions. Robust security measures embedded in the system protect patient data and maintain the highest levels of confidentiality, fostering trust and confidence among patients and stakeholders.

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement and other continued listing requirements of Nasdaq; the Company’s stockholders’ equity as of the Company’s next fiscal quarter end, which is required to be above $2.5 million pursuant to correspondence from Nasdaq; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

FAQ

What new telemedicine platform has MangoRx (MGRX) implemented?

MangoRx has successfully migrated to a DEA-approved telemedicine platform, which allows their third-party doctor network to prescribe controlled substances and offers enhanced capabilities for patient care and product offerings.

When does MangoRx (MGRX) plan to launch its new weight loss products?

MangoRx anticipates launching its new weight loss products, Slim and Trim, featuring Semaglutide and Tirzepatide in oral dissolvable tablets, before the end of the third quarter of 2024.

What improvements has MangoRx (MGRX) made to its website?

MangoRx has unveiled a redesigned consumer-facing website with an improved user interface and user experience (UI/UX), optimized for enhanced customer workflows and operational efficiency.

How does the new telemedicine platform benefit MangoRx's (MGRX) product offerings?

The new DEA-approved platform allows MangoRx to offer a broader range of products, including controlled substances like Prime by MangoRx (an Oral Testosterone Replacement Therapy), and has accelerated the timeline for introducing new product lines such as weight loss treatments.